Murdoch Children's R327 Efficacy UTI in-vivo
Filed with ASX · · 4 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- RCE Awarded Further $11.17m Advanced Overseas Finding
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
- Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
- Canadian Patent Granted for RECCE Anti-Infectives
- Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
Later from Recce Pharmaceuticals
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
- RCE Establishes Strategic Partnership in South-East Asia
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- Recce Receives AUD $11.17m R&D Advance
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals